Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
- PMID: 33969170
- PMCID: PMC8088590
- DOI: 10.1002/dad2.12173
Standardizing salivary lactoferrin measurements to obtain a robust diagnostic biomarker for Alzheimer's disease
Abstract
The search for new, robust, and reproducible biomarkers for Alzheimer's disease (AD) diagnosis is a challenge. We recently reported that salivary lactoferrin (Lf) could be presented as new biomarker candidate for AD, being both non-invasive and cost-effective, as well as having appropriate diagnostic performance for the clinical detection of AD subjects. Saliva is an attractive sample type for biomarker-based testing approaches for several other diseases; however, its composition may change under certain circumstances. It is therefore critical to maintain a consistent salivary handling protocol, considering possible extrinsic factors that may influence salivary Lf concentration. In this work, we analyzed salivary Lf concentration under different handling conditions and donor-dependent factors including age, inter-diurnal variations, physical activity, and pharmacological treatments. Our aim was to evaluate the influence of such conditions on salivary Lf concentration. In conclusion, we found that most of these extrinsic factors should be considered in the future when using Lf as a predictive biomarker for AD.
Keywords: Alzheimer's disease; aging; biomarker; circadian rhythm; exercise; lactoferrin; measurement; regulatory factors; reproducibility; saliva; treatments.
© 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.
Conflict of interest statement
Dr. Eva Carro and Dr. Gorka Orive are co‐founders of GEROA Diagnostics. No other disclosures are reported.
Figures
Similar articles
-
Decreased salivary lactoferrin levels are specific to Alzheimer's disease.EBioMedicine. 2020 Jul;57:102834. doi: 10.1016/j.ebiom.2020.102834. Epub 2020 Jun 22. EBioMedicine. 2020. PMID: 32586758 Free PMC article.
-
Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: A hypothesis.Med Hypotheses. 2021 Jan;146:110393. doi: 10.1016/j.mehy.2020.110393. Epub 2020 Nov 13. Med Hypotheses. 2021. PMID: 33229194
-
Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.Alzheimers Dement. 2020 Aug;16(8):1196-1204. doi: 10.1002/alz.12107. Epub 2020 Jun 16. Alzheimers Dement. 2020. PMID: 32543760 Free PMC article.
-
Saliva, an easily accessible fluid as diagnostic tool and potent stem cell source for Alzheimer's Disease: Present and future applications.Brain Res. 2020 Jan 15;1727:146535. doi: 10.1016/j.brainres.2019.146535. Epub 2019 Oct 25. Brain Res. 2020. PMID: 31669827 Review.
-
Salivary Biomarkers for Alzheimer's Disease: A Systematic Review with Meta-Analysis.Int J Mol Sci. 2024 Jan 18;25(2):1168. doi: 10.3390/ijms25021168. Int J Mol Sci. 2024. PMID: 38256241 Free PMC article. Review.
Cited by
-
Reduced Salivary Lactoferrin Levels in Early-Onset Alzheimer's Disease.Aging Dis. 2024 May 7;15(3):945-947. doi: 10.14336/AD.2023.0819. Aging Dis. 2024. PMID: 37815910 Free PMC article. No abstract available.
-
Obtaining a Reliable Diagnostic Biomarker for Diabetes Mellitus by Standardizing Salivary Glucose Measurements.Biomolecules. 2022 Sep 21;12(10):1335. doi: 10.3390/biom12101335. Biomolecules. 2022. PMID: 36291544 Free PMC article.
-
Lactoferrin as Immune-Enhancement Strategy for SARS-CoV-2 Infection in Alzheimer's Disease Patients.Front Immunol. 2022 Apr 25;13:878201. doi: 10.3389/fimmu.2022.878201. eCollection 2022. Front Immunol. 2022. PMID: 35547737 Free PMC article. Review.
-
Salivary Lactoferrin Expression in a Mouse Model of Alzheimer's Disease.Front Immunol. 2021 Sep 30;12:749468. doi: 10.3389/fimmu.2021.749468. eCollection 2021. Front Immunol. 2021. PMID: 34659251 Free PMC article.
References
-
- Olsen I, Singhrao SK. Low levels of salivary lactoferrin may affect oral dysbiosis and contribute to Alzheimer's disease: a hypothesis. Med Hypotheses. 2021;146:110393. - PubMed
-
- Glimvall P, Wickström C, Jansson H. Elevated levels of salivary lactoferrin, a marker for chronic periodontitis?. J Periodontal Res. 2012;47:655‐660. - PubMed
LinkOut - more resources
Full Text Sources